Brentuximab Vedotin Combined With AVD Chemotherapy and Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (NCT01868451)
The purpose of this study is to find out whether brentuximab vedotin with AVD chemotherapy and radiation is a safe and effective treatment. It is hoped that this treatment will improve the ability to cure more patients with HL.
This trial is sponsored by Memorial Sloan Kettering Cancer Center 
- Condition: Hodgkin Lymphoma
- Drugs used in this trial
- Device: Dacarbazine
- Radiation: Involved-Site Radiation Therapy (ISRT)
- Procedure: Interim PET
- Interim PET Drug: Filgrastim (Neupogen®; Amgen)
- Phase: 0
- Estimated Enrollment: 59
- Start: May 2013
- Estimated Completion: May 2016
- Last verified: May 2015
Last Editorial review: July 10, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.